Scott Wolchko | President and Chief Executive Officer |
Daniel Shoemaker | Chief Scientific Officer |
Wayne Chu | Senior Vice President of Clinical Development |
Mara Goldstein | Mizuho Securities USA LLC |
Alethia Young | Cantor Fitzgerald & Co. |
James Birchenough | Wells Fargo Securities, LLC |
Edward Tenthoff | Piper Sandler & Co. |
Benjamin Burnett | Stifel, Nicolaus & Company, Inc. |
Kelsey Goodwin | Guggenheim Securities, LLC |
Biren Amin | Jefferies LLC |
Matthew Biegler | Oppenheimer & Co. Inc. |
Amanda Murphy | BTIG, LLC |
Welcome to the Fate Therapeutics' Fourth Quarter 2019 Financial Results Conference Call. At this time, all participants are in a listen-only mode. This call is being webcast live on the Investors and Media section of Fate's website at fatetherapeutics.com.
As a reminder, today's call is being recorded.
I would now like to introduce Scott Wolchko, President and CEO of Fate Therapeutics.